TARA-002 is a cell therapy commercialized by Protara Therapeutics, with a leading Phase I program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TARA-002’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for TARA-002 is expected to reach an annual total of $63 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
TARA-002 is under development for the treatment of cancers (lymphangiomas), rare diseases like macrocystic lymphatic malformations, ranula and non-muscle invasive bladder cancer. It is administered through intravesical route. The drug candidate acts by targeting Toll Like Receptor 4 (TLR4). TARA-002 is a lyophilized, cellular therapy based on OK-432, a genetically distinct strain of Streptococcus Pyogenes which is rendered nonvirulent through a proprietary manufacturing process. This process retains the Streptococcus antigen properties while eliminating the infectious properties of the bacteria.
Protara Therapeutics Overview
Protara Therapeutics develops transformative therapies. The company portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. Protara Therapeutics is headquartered in New York City, New York, the US.
The operating loss of the company was US$47.5 million in FY2021, compared to an operating loss of US$34.4 million in FY2020. The net loss of the company was US$47.3 million in FY2021, compared to a net loss of US$34 million in FY2020.
For a complete picture of TARA-002’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.